Literature DB >> 11030149

Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

M A Grotzer1, A Eggert, T J Zuzak, A J Janss, S Marwaha, B R Wiewrodt, N Ikegaki, G M Brodeur, P C Phillips.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in adult malignant glioma and various other human solid tumor models but not in normal tissues. To characterize the TRAIL death pathway in childhood primitive neuroectodermal brain tumor (PNET), 8 human PNET cell lines were tested for TRAIL-induced apoptosis. TRAIL-sensitivity of the PNET cell lines was correlated with mRNA expression levels of TRAIL, its agonistic (TRAIL-R1, TRAIL-R2) and antagonistic (TRAIL-R3, TRAIL-R4) receptors, cellular FLICE-like inhibitory protein (cFLIP), caspase-3 and caspase-8. Three of 8 PNET cell lines tested were susceptible to TRAIL-induced apoptosis. Sensitivity to TRAIL-induced apoptosis did not correlate with mRNA expression of TRAIL receptors or cFLIP. However, all TRAIL-sensitive PNET cell lines expressed caspase-8 mRNA and protein, while none of the five TRAIL-resistant PNET cell lines expressed caspase-8 protein. Treatment with the methyltransferase inhibitor 5-aza-2'-deoxycytidine restored mRNA expression of caspase-8 and TRAIL-sensitivity in formerly TRAIL-resistant PNET cells, suggesting that gene methylation inhibits caspase-8 transcription in these cells. We conclude, that loss of caspase-8 mRNA is an important mechanism of TRAIL-resistance in PNET cells. Treatment with recombinant soluble TRAIL, possibly in combination with methyltransferase inhibitors, represents a promising therapeutic approach for PNET that deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030149     DOI: 10.1038/sj.onc.1203816

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

2.  TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

Authors:  Johannes Lemke; Andreas Noack; Dieter Adam; Vladimir Tchikov; Uwe Bertsch; Christian Röder; Stefan Schütze; Harald Wajant; Holger Kalthoff; Anna Trauzold
Journal:  J Mol Med (Berl)       Date:  2010-03-31       Impact factor: 4.599

3.  Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.

Authors:  Juan Yuan; Núria Llamas Luceño; Bjoern Sander; Monika M Golas
Journal:  Cell Oncol (Dordr)       Date:  2017-04-20       Impact factor: 6.730

4.  Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro.

Authors:  Jian Chen; Xiaobai Sun; Weihua Yang; Guosheng Jiang; Xingang Li
Journal:  Tumour Biol       Date:  2010-07-11

5.  The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death.

Authors:  Roslyn N Crowder; David T Dicker; Wafik S El-Deiry
Journal:  J Biol Chem       Date:  2016-01-12       Impact factor: 5.157

6.  Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.

Authors:  Carsten Friedrich; Tarek Shalaby; Christoph Oehler; Martin Pruschy; Burkhardt Seifert; Daniel Picard; Marc Remke; Monika Warmuth-Metz; Rolf-Dieter Kortmann; Stefan Rutkowski; Michael A Grotzer; André O von Bueren
Journal:  Childs Nerv Syst       Date:  2017-07-10       Impact factor: 1.475

Review 7.  Caspase-8 as a therapeutic target in cancer.

Authors:  Dwayne G Stupack
Journal:  Cancer Lett       Date:  2010-09-03       Impact factor: 8.679

Review 8.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.

Authors:  Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

9.  Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.

Authors:  Bernhard Gillissen; Jana Wendt; Antje Richter; Anja Richter; Annika Müer; Tim Overkamp; Nina Gebhardt; Robert Preissner; Claus Belka; Bernd Dörken; Peter T Daniel
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

10.  In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus.

Authors:  Fang Li; Yi Guo; Lingfei Han; Yankang Duan; Fang Fang; Sumei Niu; Qiujie Ba; Huaishi Zhu; Fanfei Kong; Chao Lin; Xuejun Wen
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.